vs
Side-by-side financial comparison of Employers Holdings, Inc. (EIG) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $170.5M, roughly 1.0× Employers Holdings, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -21.3%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -11.4%).
Employers Holdings, Inc. is a U.S.-headquartered insurance holding company that specializes in offering workers' compensation insurance and customized risk management services primarily for small and medium-sized enterprises across the United States. It mainly serves clients in low-to-medium hazard industries, helping them mitigate workplace safety risks and meet relevant regulatory requirements for employee protection.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
EIG vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $170.5M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | -21.3% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $170.5M | $177.4M | ||
| Q4 25 | $188.5M | $196.9M | ||
| Q3 25 | $239.3M | $179.5M | ||
| Q2 25 | $246.3M | $181.1M | ||
| Q1 25 | $202.6M | $168.9M | ||
| Q4 24 | $216.6M | $187.3M | ||
| Q3 24 | $224.0M | $168.6M | ||
| Q2 24 | $217.0M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-8.3M | $5.4M | ||
| Q2 25 | $29.7M | $-4.8M | ||
| Q1 25 | $12.8M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $30.3M | $-143.5M | ||
| Q2 24 | $31.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | -4.7% | 3.5% | ||
| Q2 25 | 15.0% | 4.7% | ||
| Q1 25 | 7.8% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 16.4% | -82.8% | ||
| Q2 24 | 18.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | -3.5% | 3.0% | ||
| Q2 25 | 12.1% | -2.7% | ||
| Q1 25 | 6.3% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.5% | -85.1% | ||
| Q2 24 | 14.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.93 | $0.05 | ||
| Q3 25 | $-0.36 | $0.12 | ||
| Q2 25 | $1.23 | $-0.11 | ||
| Q1 25 | $0.52 | $0.10 | ||
| Q4 24 | $1.14 | $0.38 | ||
| Q3 24 | $1.21 | $-3.11 | ||
| Q2 24 | $1.25 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $169.9M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $955.7M | $653.9M |
| Total Assets | $3.4B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $169.9M | $144.3M | ||
| Q4 25 | $169.9M | $238.4M | ||
| Q3 25 | $172.4M | $246.3M | ||
| Q2 25 | $78.1M | $445.9M | ||
| Q1 25 | $100.4M | $493.6M | ||
| Q4 24 | $68.4M | $484.6M | ||
| Q3 24 | $173.9M | $453.8M | ||
| Q2 24 | $126.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $19.0M | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $0 | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $955.7M | $653.9M | ||
| Q4 25 | $955.7M | $693.1M | ||
| Q3 25 | $1.0B | $727.2M | ||
| Q2 25 | $1.1B | $757.8M | ||
| Q1 25 | $1.1B | $798.5M | ||
| Q4 24 | $1.1B | $778.3M | ||
| Q3 24 | $1.1B | $749.6M | ||
| Q2 24 | $1.0B | $879.3M |
| Q1 26 | $3.4B | $1.2B | ||
| Q4 25 | $3.4B | $1.3B | ||
| Q3 25 | $3.5B | $1.3B | ||
| Q2 25 | $3.5B | $1.5B | ||
| Q1 25 | $3.6B | $1.6B | ||
| Q4 24 | $3.5B | $1.6B | ||
| Q3 24 | $3.6B | $1.5B | ||
| Q2 24 | $3.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.02× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.00× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EIG
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
